Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Sato K, Naganuma A, Nagashima T, Hoshino T, Uehara D, Arai Y, Horiuchi K, Yuasa K, Takayama H, Arai H, Hatanaka T, Ohyama T, Tahara H, Sohara N, Kobayashi T, Horiguchi N, Yamazaki Y, Kakizaki S, Kusano M, Yamada M, Murase T, Nakamura T.
Sato K, et al. Among authors: yuasa k.
Hepatol Res. 2018 Feb;48(3):E347-E353. doi: 10.1111/hepr.12971. Epub 2017 Sep 25.
Hepatol Res. 2018.
PMID: 28834004